Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.47 |
| ▸ | NOS2 | P35228 | 3/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
| ▸ | GABRE | P78334 | 1/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30736300 | 1.00 | NOS3 (0.47) | NOS3NOS2NOS1GABRPGABRD | |
| Hydrochloric Acid SCHEMBL29960928 | 0.98 | NOS3 (0.46) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL13016581 | 0.84 | NOS3 (0.35) | NOS3NOS2NOS1PDGFRBKDR | |
| SCHEMBL29977691 | 0.82 | UHRF1 (0.39) | — | |
| SCHEMBL16754496 | 0.82 | UHRF1 (0.39) | — | |
| SCHEMBL2814938 | 0.81 | LPL (0.34) | NOS3NOS2NOS1PDGFRBKDR | |
| SCHEMBL2818121 | 0.81 | NOS3 (0.33) | NOS3NOS2NOS1PDGFRBKDR | |
| SCHEMBL14245043 | 0.79 | CHRNB2 (0.31) | — | |
| SCHEMBL17859746 | 0.79 | EGFR (0.38) | NOS3NOS2NOS1PIK3CAMTOR | |
| SCHEMBL20519666 | 0.79 | NOS3 (0.45) | NOS3NOS2NOS1GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2025-12-18 | — | — | US | disclosed |
| EP-3313828-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023104035-A1 | SUBSTITUTED MONOCYCLIC OR BICYCLIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 英矽智能科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-11548867-B2 | Amido compounds as AhR modulators | IDEA YA BIOSCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220340875-A1 | METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS | IDEAYA BIOSCIENCES, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220204498-A1 | PYRIDO-PYRIMIDINYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2022-06-30 | — | — | US | disclosed |
| US-20220204498-A1 | PYRIDO-PYRIMIDINYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2022-06-30 | — | — | US | disclosed |
| EP-3927433-A1 | PYRIDO-PYRIMIDINYL COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2021-12-29 | — | — | EP | disclosed |
| CN-113795307-A | Pyridopyrimidinyl compounds and methods of use thereof | 基因泰克公司 | 2021-12-14 | — | — | CN | disclosed |
| US-20210115016-A1 | AMIDO COMPOUNDS AS AhR MODULATORS | IDEAYA BIOSCIENCES, INC. | 2021-04-22 | — | — | US | disclosed |
| US-9708336-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| EP-3096754-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9499561-B2 | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-20160333021-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SOUTHERN RESEARCH INSTITUTE | 2016-06-09 | — | — | US | disclosed |
| WO-2016090296-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | ANANTHAN SUBRAMANIAM (US) | 2016-06-09 | — | — | WO | disclosed |
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | SHANGHAI YUNYI HEALTHCARE AND TECHNOLOGY CO., LTD. (CN) | 2015-09-03 | — | — | US | disclosed |
| WO-2015112441-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | FGFR3, FGFR2, FGFR1 | NOS3 4684/4885NOS2 4566/4885NOS1 4554/4885 |
| US-20220204498-A1 | PYRIDO-PYRIMIDINYL COMPOUNDS AND METHODS OF USE | XBP1, HSPA5, ERN2 | NOS3 4253/4885NOS2 4442/4885NOS1 4418/4885 |
| US-20220340875-A1 | METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS | AHR, MCL1, ARNT | NOS3 906/4885NOS2 825/4885NOS1 1301/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | NOS3 100/4885NOS2 94/4885NOS1 93/4885 |
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SLC18A2, SLC6A2, SLC6A3 | NOS3 872/4885NOS2 956/4885NOS1 689/4885 |
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | NOS3 2929/4885NOS2 3872/4885NOS1 3474/4885 |
| US-20210115016-A1 | AMIDO COMPOUNDS AS AhR MODULATORS | AHR, ARNT, RXRB | NOS3 751/4885NOS2 644/4885NOS1 979/4885 |
| US-11548867-B2 | Amido compounds as AhR modulators | AHR, ARNT, RXRB | NOS3 751/4885NOS2 644/4885NOS1 979/4885 |
| US-20160333021-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, GAA | NOS3 2954/4885NOS2 1802/4885NOS1 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.